Back to search results

A Study of Enzalutamide Plus the Glucocorticoid Receptor Antagonist Relacorilant Versus Placebo for Patients With High-risk Localized Prostate Cancer

Abroad (travel likely)RecruitingPHASE2

Conditions

Prostate Cancer · Prostate Adenocarcinoma

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

  • University of Chicago Comprehensive Cancer Center, Chicago, Illinois, United States

    Contact: Study coordinator (Cancer Trials) · cancerclinicaltrials@bsd.uchicago.edu · 855-702-8222
    Contact: Principal Investigator (Russell Szmulewitz, MD)

  • University of Texas Southwestern Medical Center, Dallas, Texas, United States

    Contact: Study coordinator (Amy Rowell) · amy.rowell@utsouthwestern.edu · 214-645-9688
    Contact: Principal Investigator (Kevin Courtney)
Study leads

  • Russell Szmulewitz, MD

    Principal Investigator

    University of Chicago

View source on ClinicalTrials.gov(opens in a new tab)Contact study team (email)